Skip to Content

Neumega (oprelvekin) Disease Interactions

There are 4 disease interactions with Neumega (oprelvekin):

Major

Oprelvekin (Includes Neumega) ↔ Fluid Retention

Severe Potential Hazard, High plausibility

Applies to: Hypokalemia, Fluid Retention, Congestive Heart Failure

Oprelvekin causes fluid retention that can result in peripheral edema, dyspnea on exertion, pulmonary edema, atrial arrhythmias, dilution decreases in hemoglobin and hematocrit and changes in serum electrolyte concentrations. Therapy with oprelvekin should be administered cautiously in patients adversely affected by fluid retention, such as patients with congestive heart failure. Clinical monitoring of fluid status and electrolyte levels is recommended.

References

  1. "Product Information. Neumega (oprelvekin)." Genetics Institute, Cambridge, MA.
Moderate

Oprelvekin (Includes Neumega) ↔ Arrhythmias

Moderate Potential Hazard, High plausibility

Applies to: Arrhythmias

Transient artrial arrhythmias (fibrillation and flutter) have occurred in approximately 10% of patients receiving oprelvekin. Cardiac conditions, previous cardiotoxic chemotherapy, or advanced age are considered risk factors for development of oprelvekin- associated arrhythmias. Therapy with oprelvekin should be administered cautiously in patients with or predisposed to artrial arrhythmias.

References

  1. "Product Information. Neumega (oprelvekin)." Genetics Institute, Cambridge, MA.
Moderate

Oprelvekin (Includes Neumega) ↔ Papilledema

Moderate Potential Hazard, Moderate plausibility

Applies to: Brain/Intracranial Tumor

Papilledema has been reported in 2% of patients receiving oprelvekin. Therapy with oprelvekin should be administered cautiously in patients with papilledema or CNS tumors as papilledema can be worsened or induced during therapy.

References

  1. "Product Information. Neumega (oprelvekin)." Genetics Institute, Cambridge, MA.
Moderate

Oprelvekin (Includes Neumega) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Oprelvekin is primarily eliminated by the kidneys and drug exposure was significantly increased in patients with severe renal impairment (CrCl <30 mL/min). The recommended dose in these patients is 50 mcg/kg once a day. No significant changes were observed in patients with mild or moderate impairment. Fluid retention associated with oprelvekin has not been studied in patients with renal impairment, but fluid balance should be carefully monitored in these patients.

Neumega (oprelvekin) drug Interactions

There are 3 drug interactions with Neumega (oprelvekin)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide